Osteoclast-Released Wnt-10b Underlies Cinacalcet Related Bone Improvement in Chronic Kidney Disease
Secondary hyperparathyroidism (SHPT) relates to high turnover bone loss and is responsible for most bone fractures among chronic kidney disease (CKD) patients. Changes in the Wingless/beta-catenin signaling (Wnt/β-catenin) pathway and Wnt inhibitors have been found to play a critical role i...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-06-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/20/11/2800 |
id |
doaj-5d3c306c882340dfae654fe880c0fec4 |
---|---|
record_format |
Article |
spelling |
doaj-5d3c306c882340dfae654fe880c0fec42020-11-25T01:14:03ZengMDPI AGInternational Journal of Molecular Sciences1422-00672019-06-012011280010.3390/ijms20112800ijms20112800Osteoclast-Released Wnt-10b Underlies Cinacalcet Related Bone Improvement in Chronic Kidney DiseaseCai-Mei Zheng0Yung-Ho Hsu1Chia-Chao Wu2Chien-Lin Lu3Wen-Chih Liu4Jing-Quan Zheng5Yuh-Feng Lin6Hui-Wen Chiu7Tian-Jong Chang8Jia-Fwu Shyu9Kuo-Cheng Lu10Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 110, TaiwanGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 110, TaiwanDivision of Nephrology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 10581, TaiwanGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 110, TaiwanGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 110, TaiwanGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 110, TaiwanGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 110, TaiwanGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 110, TaiwanGraduate Institute of Life Sciences, National Defense Medical Center, Taipei 114, TaiwanGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 110, TaiwanGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 110, TaiwanSecondary hyperparathyroidism (SHPT) relates to high turnover bone loss and is responsible for most bone fractures among chronic kidney disease (CKD) patients. Changes in the Wingless/beta-catenin signaling (Wnt/β-catenin) pathway and Wnt inhibitors have been found to play a critical role in CKD related bone loss. A calcimimetic agent, cinacalcet, is widely used for SHPT and found to be similarly effective for parathyroidectomy clinically. A significant decrease in hip fracture rates is noted among US hemodialysis Medicare patients since 2004, which is probably related to the cinacalcet era. In our previous clinical study, it was proven that cinacalcet improved the bone mineral density (BMD) even among severe SHPT patients. In this study, the influence of cinacalcet use on bone mass among CKD mice was determined. Cinacalcet significantly reduced the cortical porosity in femoral bones of treated CKD mice. It also improved the whole-bone structural properties through increased stiffness and maximum load. Cinacalcet increased femoral bone wingless 10b (Wnt10b) expression in CKD mice. In vitro studies revealed that cinacalcet decreased osteoclast bone resorption and increased Wnt 10b release from osteoclasts. Cinacalcet increased bone mineralization when culturing the osteoblasts with cinacalcet treated osteoclast supernatant. In conclusion, cinacalcet increased bone quantity and quality in CKD mice, probably through increased bone mineralization related with osteoclast Wnt 10b secretion.https://www.mdpi.com/1422-0067/20/11/2800cinacalcetrenal osteodystrophyosteoclastWnt 10bchronic kidney disease |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Cai-Mei Zheng Yung-Ho Hsu Chia-Chao Wu Chien-Lin Lu Wen-Chih Liu Jing-Quan Zheng Yuh-Feng Lin Hui-Wen Chiu Tian-Jong Chang Jia-Fwu Shyu Kuo-Cheng Lu |
spellingShingle |
Cai-Mei Zheng Yung-Ho Hsu Chia-Chao Wu Chien-Lin Lu Wen-Chih Liu Jing-Quan Zheng Yuh-Feng Lin Hui-Wen Chiu Tian-Jong Chang Jia-Fwu Shyu Kuo-Cheng Lu Osteoclast-Released Wnt-10b Underlies Cinacalcet Related Bone Improvement in Chronic Kidney Disease International Journal of Molecular Sciences cinacalcet renal osteodystrophy osteoclast Wnt 10b chronic kidney disease |
author_facet |
Cai-Mei Zheng Yung-Ho Hsu Chia-Chao Wu Chien-Lin Lu Wen-Chih Liu Jing-Quan Zheng Yuh-Feng Lin Hui-Wen Chiu Tian-Jong Chang Jia-Fwu Shyu Kuo-Cheng Lu |
author_sort |
Cai-Mei Zheng |
title |
Osteoclast-Released Wnt-10b Underlies Cinacalcet Related Bone Improvement in Chronic Kidney Disease |
title_short |
Osteoclast-Released Wnt-10b Underlies Cinacalcet Related Bone Improvement in Chronic Kidney Disease |
title_full |
Osteoclast-Released Wnt-10b Underlies Cinacalcet Related Bone Improvement in Chronic Kidney Disease |
title_fullStr |
Osteoclast-Released Wnt-10b Underlies Cinacalcet Related Bone Improvement in Chronic Kidney Disease |
title_full_unstemmed |
Osteoclast-Released Wnt-10b Underlies Cinacalcet Related Bone Improvement in Chronic Kidney Disease |
title_sort |
osteoclast-released wnt-10b underlies cinacalcet related bone improvement in chronic kidney disease |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1422-0067 |
publishDate |
2019-06-01 |
description |
Secondary hyperparathyroidism (SHPT) relates to high turnover bone loss and is responsible for most bone fractures among chronic kidney disease (CKD) patients. Changes in the Wingless/beta-catenin signaling (Wnt/β-catenin) pathway and Wnt inhibitors have been found to play a critical role in CKD related bone loss. A calcimimetic agent, cinacalcet, is widely used for SHPT and found to be similarly effective for parathyroidectomy clinically. A significant decrease in hip fracture rates is noted among US hemodialysis Medicare patients since 2004, which is probably related to the cinacalcet era. In our previous clinical study, it was proven that cinacalcet improved the bone mineral density (BMD) even among severe SHPT patients. In this study, the influence of cinacalcet use on bone mass among CKD mice was determined. Cinacalcet significantly reduced the cortical porosity in femoral bones of treated CKD mice. It also improved the whole-bone structural properties through increased stiffness and maximum load. Cinacalcet increased femoral bone wingless 10b (Wnt10b) expression in CKD mice. In vitro studies revealed that cinacalcet decreased osteoclast bone resorption and increased Wnt 10b release from osteoclasts. Cinacalcet increased bone mineralization when culturing the osteoblasts with cinacalcet treated osteoclast supernatant. In conclusion, cinacalcet increased bone quantity and quality in CKD mice, probably through increased bone mineralization related with osteoclast Wnt 10b secretion. |
topic |
cinacalcet renal osteodystrophy osteoclast Wnt 10b chronic kidney disease |
url |
https://www.mdpi.com/1422-0067/20/11/2800 |
work_keys_str_mv |
AT caimeizheng osteoclastreleasedwnt10bunderliescinacalcetrelatedboneimprovementinchronickidneydisease AT yunghohsu osteoclastreleasedwnt10bunderliescinacalcetrelatedboneimprovementinchronickidneydisease AT chiachaowu osteoclastreleasedwnt10bunderliescinacalcetrelatedboneimprovementinchronickidneydisease AT chienlinlu osteoclastreleasedwnt10bunderliescinacalcetrelatedboneimprovementinchronickidneydisease AT wenchihliu osteoclastreleasedwnt10bunderliescinacalcetrelatedboneimprovementinchronickidneydisease AT jingquanzheng osteoclastreleasedwnt10bunderliescinacalcetrelatedboneimprovementinchronickidneydisease AT yuhfenglin osteoclastreleasedwnt10bunderliescinacalcetrelatedboneimprovementinchronickidneydisease AT huiwenchiu osteoclastreleasedwnt10bunderliescinacalcetrelatedboneimprovementinchronickidneydisease AT tianjongchang osteoclastreleasedwnt10bunderliescinacalcetrelatedboneimprovementinchronickidneydisease AT jiafwushyu osteoclastreleasedwnt10bunderliescinacalcetrelatedboneimprovementinchronickidneydisease AT kuochenglu osteoclastreleasedwnt10bunderliescinacalcetrelatedboneimprovementinchronickidneydisease |
_version_ |
1725159199405506560 |